{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Roet JEG"],"funding":["Convergence Health Technology Flagship","Cancer Center Amsterdam","NWO LymphChip","Dutch Cancer Foundation","Medical Delta: Regenerative Medicine 4D","Dutch Research Council (NWO)","ZonMw"],"pagination":["e70086"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12599485"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["55(11)"],"pubmed_abstract":["Autoimmunity can be initiated by autoreactive T cells that escaped central and peripheral tolerance induction. Peripheral tolerance in lymph nodes (LNs) is maintained by fibroblastic reticular cells (FRCs) via self-antigen presentation in major histocompatibility complex (MHC) class II. FRCs can be divided into various subsets, with specific markers, functions, and locations. FRCs located in the T-cell zone (TRCs) can express genes for antigen presentation in MHC class-II, for example, H2-Ab1 and Cd74, as well as the immune inhibitory ligand Cd200. However, whether this can be linked to MHC class-II protein expression and thus tolerance is unknown. By combining scRNAseq on murine FRCs with protein staining for extracellular MHC class-II, we confirm that murine TRCs have the highest MHC class-II transcript levels, while protein levels are elevated in multiple FRC subsets. Gene expression for MHC class-II, as well as Bst1 and Cd200, gradually increases along the pseudotime trajectory, with TRCs representing the end, indicating maturation. Finally, we validated in fresh LN cell suspensions that MHC class-II protein expression is associated with murine BST1<sup>+</sup> FRCs, independent of CD200, and with human BST1<sup>+</sup>CD200<sup>+</sup> TRCs. This mature FRC subset, equipped to maintain peripheral tolerance, could be an interesting target for therapies against autoimmune diseases."],"journal":["European journal of immunology"],"pubmed_title":["Enhanced MHC Class-II Expression in Fibroblastic Reticular Cells Associates with Maturation."],"pmcid":["PMC12599485"],"funding_grant_id":["91217014","024.002.009","CCA2019-9-57","2022-4 EXPL/14641","CCA2020-9-73","1292.19.019"],"pubmed_authors":["van der Laan LJW","Panocha D","da Graca CG","Roet JEG","Mebius RE","Roest HP","de Winde CM","Konijn T","van Baarsen LGM","de Kok M"],"additional_accession":[]},"is_claimable":false,"name":"Enhanced MHC Class-II Expression in Fibroblastic Reticular Cells Associates with Maturation.","description":"Autoimmunity can be initiated by autoreactive T cells that escaped central and peripheral tolerance induction. Peripheral tolerance in lymph nodes (LNs) is maintained by fibroblastic reticular cells (FRCs) via self-antigen presentation in major histocompatibility complex (MHC) class II. FRCs can be divided into various subsets, with specific markers, functions, and locations. FRCs located in the T-cell zone (TRCs) can express genes for antigen presentation in MHC class-II, for example, H2-Ab1 and Cd74, as well as the immune inhibitory ligand Cd200. However, whether this can be linked to MHC class-II protein expression and thus tolerance is unknown. By combining scRNAseq on murine FRCs with protein staining for extracellular MHC class-II, we confirm that murine TRCs have the highest MHC class-II transcript levels, while protein levels are elevated in multiple FRC subsets. Gene expression for MHC class-II, as well as Bst1 and Cd200, gradually increases along the pseudotime trajectory, with TRCs representing the end, indicating maturation. Finally, we validated in fresh LN cell suspensions that MHC class-II protein expression is associated with murine BST1<sup>+</sup> FRCs, independent of CD200, and with human BST1<sup>+</sup>CD200<sup>+</sup> TRCs. This mature FRC subset, equipped to maintain peripheral tolerance, could be an interesting target for therapies against autoimmune diseases.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-05T13:17:04.278Z","creation":"2026-05-17T03:12:45.261Z"},"accession":"S-EPMC12599485","cross_references":{"pubmed":["41211809"],"doi":["10.1002/eji.70086"]}}